State College, PA, United States

Ascent Bio-Nano Technologies, Inc.

www.AscentBioNano.com
State College, PA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Ascent Bio-Nano Technologies, Inc. | Date: 2017-04-12

A sound manipulation system is provided. The sound manipulation system includes a flow chamber arranged and disposed to receive a fluid containing a particulate and provide in-line sound wave manipulation of at least a portion of the particulate from the fluid, and a transducer positioned to facilitate the in-line sound wave manipulation within the flow chamber. The flow chamber includes at least a first portion and a second portion, the first portion being self-aligned and secured to the second portion.


Patent
Ascent Bio-Nano Technologies, Inc. | Date: 2015-06-09

A sound manipulation system is provided. The sound manipulation system includes a flow chamber arranged and disposed to receive a fluid containing a particulate and provide in-line sound wave manipulation of at least a portion of the particulate from the fluid, and a transducer positioned to facilitate the in-line sound wave manipulation within the flow chamber. The flow chamber includes at least a first portion and a second portion, the first portion being self-aligned and secured to the second portion.


Chen Y.,Pennsylvania State University | Nawaz A.A.,Pennsylvania State University | Zhao Y.,Pennsylvania State University | Huang P.-H.,Pennsylvania State University | And 4 more authors.
Lab on a Chip - Miniaturisation for Chemistry and Biology | Year: 2014

The development of microfluidic chip-based cytometers has become an important area due to their advantages of compact size and low cost. Herein, we demonstrate a sheathless microfluidic cytometer which integrates a standing surface acoustic wave (SSAW)-based microdevice capable of 3D particle/cell focusing with a laser-induced fluorescence (LIF) detection system. Using SSAW, our microfluidic cytometer was able to continuously focus microparticles/cells at the pressure node inside a microchannel. Flow cytometry was successfully demonstrated using this system with a coefficient of variation (CV) of less than 10% at a throughput of ~1000 events s-1 when calibration beads were used. We also demonstrated that fluorescently labeled human promyelocytic leukemia cells (HL-60) could be effectively focused and detected with our SSAW-based system. This SSAW-based microfluidic cytometer did not require any sheath flows or complex structures, and it allowed for simple operation over a wide range of sample flow rates. Moreover, with the gentle, bio-compatible nature of low-power surface acoustic waves, this technique is expected to be able to preserve the integrity of cells and other bioparticles. This journal is © The Royal Society of Chemistry 2014.


Chen Y.,Pennsylvania State University | Li P.,Pennsylvania State University | Huang P.-H.,Pennsylvania State University | Xie Y.,Pennsylvania State University | And 4 more authors.
Lab on a Chip - Miniaturisation for Chemistry and Biology | Year: 2014

Rare cells are low-abundance cells in a much larger population of background cells. Conventional benchtop techniques have limited capabilities to isolate and analyze rare cells because of their generally low selectivity and significant sample loss. Recent rapid advances in microfluidics have been providing robust solutions to the challenges in the isolation and analysis of rare cells. In addition to the apparent performance enhancements resulting in higher efficiencies and sensitivity levels, microfluidics provides other advanced features such as simpler handling of small sample volumes and multiplexing capabilities for high-throughput processing. All of these advantages make microfluidics an excellent platform to deal with the transport, isolation, and analysis of rare cells. Various cellular biomarkers, including physical properties, dielectric properties, as well as immunoaffinities, have been explored for isolating rare cells. In this Focus article, we discuss the design considerations of representative microfluidic devices for rare cell isolation and analysis. Examples from recently published works are discussed to highlight the advantages and limitations of the different techniques. Various applications of these techniques are then introduced. Finally, a perspective on the development trends and promising research directions in this field are proposed. © 2014 The Royal Society of Chemistry.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2015

DESCRIPTION provided by applicant Asthma is a chronic lung disease that causes the airways in the lungs to become inflamed making it difficult to breathe and leading to episodes of intense coughing and wheezing Frequently the symptoms of asthma require hospitalization for treatment and in rare cases can lead to death Unfortunately the prevalence of asthma has increased rapidly over the past several decades and more than in Americans are now living with the disease While there is no cure for asthma the symptoms of the disease can be managed through a series of prescription medicines However this conventional one size fits all therapeutic approach fails to account for the different clinical forms and phenotypes of asthma which have been the subject of many recent medical studies By analyzing the different cell populations found in sputum the mucus within the airways of the lungs researchers have identified the distinct immunological phenotypes associated with the disease Identifying these phenotypes has led to hopes of developing individually tailored therapeutic treatments that will more effectively target the mechanisms unique to each phenotype Although sputum analysis has proven to be a powerful tool that provides a noninvasive means of characterizing the different variations of asthma the current methods for processing and analyzing sputum are complex and labor intensive The multi step process requires highly trained personnel and the amount of sputum collected from a patient is often too small to perform meaningful analysis In addition the process requires the use of expensive benchtop equipment which prevents point of care applications and limits the analysis to centralized facilities As a result there exists a critical need in the medical community for a more simple and rapid approach for processing and analyzing low volume sputum samples Recently we have developed a series of acoustofluidic i e fusion of acoustics and microfluidics technologies which collectively perform the necessary functions for sputum processing and analysis We have demonstrated the first sharp edge based acoustofluidic mixer the first surface acoustic wave SAW based cell separator and the first SAW focusing microflow cytometer Our goal is to demonstrate the ability of each acoustofluidic based technique to perform its function in relation to the processing and analyzing low volume sputum samples Specifically we will develop and characterize an acoustofluidic sputum liquefying unit develop an acoustofluidic unit for the on chip transfer of immune cells from liquefied sputum sample to phosphate buffered saline PBS and demonstrate an acoustofluidic flow cytometry unit that accurately analyzes immune cells from induced sputum samples In each aim we will compare the results obtained from our acoustofluidic units to those obtained by their conventional counterparts Our long term goal is to integrate the three acoustofluidic units to develop an easy to use point of care device We believe advances in this area will be critical in the development of personalized treatments for asthma and may also find use in monitoring and treating other respiratory diseases and infections PUBLIC HEALTH RELEVANCE The proposed project is to develop tools that can perform point of care sputum processing and analysis from low volume samples Advances achieved in the proposed project will be critical in the development of personalized treatments for asthma End of Abstract


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: STTR PHASE II | Award Amount: 750.00K | Year: 2015

The broader/commercial impact of the Small Business Technology Transfer (STTR) Phase II project will be a cell sorter, a new research tool for life science research, animal reproduction, and cell-based therapy. In the past decade, cell sorters have become vital in many fields, such as molecular and cellular biology, immunology, plant biology, animal reproduction, and medical diagnostics and therapeutics. Despite their significant impact, current cell sorters have the following drawbacks: high equipment and maintenance costs, significant bio-safety concerns, and reduced cell viability and function. These drawbacks reduce the effectiveness of cell sorters in many important research studies and clinical applications. Enabled by this innovation, researchers will be able to better understand the causes of diseases, identify new therapies, and test new drugs and vaccines. It also has the potential to improve dairy production efficiency, and aid medical doctors in making better decisions about diagnosis and treatment. In Phase II, the goal is to improve performance of the instrument, and validate the performance with end users.

This STTR Phase II project will demonstrate the feasibility of a microfluidic-based, bio-compatible, bio-safe, fluorescence-activated cell sorter. Cell sorters are powerful, high-throughput, single-cell characterization and purification tools that are vital for labs in fields such as molecular biology, pathology, plant biology, stem cell biology, and medical diagnostics. The technology is based on acoustofluidic (i.e., the fusion of acoustics and microfluidics) cell sorting chips that preserve the integrity and functionality of sorted cells. Current cell sorting systems reduce cell viability, integrity, and cell function due to high shear stress, high impact force, and high driving voltage, which reduces their effectiveness as a research tool, and in clinical applications. Unlike current cell sorters that use electrostatic force to sort cells, which require 12,000 V of driving voltage, the proposed technology uses acoustic tweezers to sort cells, and requires only 10 V, which significantly reduces cell damage. Compared with existing cell sorters, the proposed microfluidic cell sorter will have the following advantages: 1) high bio-compatibility; 2) high bio-safety; and 3) lower costs and lower maintenance. In addition, the cell sorter will be more accessible to researchers and address existing unmet needs in the market (e.g., sorting fragile or sensitive cells while preserving high viability and function). This will accelerate research findings and improve diagnostics and therapeutics.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 730.53K | Year: 2016

Project Summary Asthma is a chronic lung disease that causes the airways in the lungs to become inflamed making it difficult to breathe and leading to episodes of intense coughing and wheezing The prevalence of asthma has increased rapidly over the past several decades and more than in Americans are now living with the disease While there is no cure for asthma the symptoms of the disease can be managed through a series of prescription medicines However this conventional one size fits all therapeutic approach fails to account for the different clinical forms and phenotypes of asthma which have been the subject of many recent medical studies By analyzing the different cell populations found in sputum the mucus within the airways of the lungs researchers have identified the distinct immunological phenotypes associated with the disease Identifying these phenotypes has led to hopes of developing individually tailored therapeutic treatments that will more effectively target the mechanisms unique to each phenotype Although sputum analysis has proven to be a powerful tool that provides a noninvasive means of characterizing the different variations of asthma the current methods for processing and analyzing sputum are complex and labor intensive The multi step process requires highly trained personnel and the amount of sputum collected from a patient is often too small to perform meaningful analysis In addition the process requires the use of expensive benchtop equipment which prevents point of care applications and limits the analysis to centralized facilities As a result there exists a critical need in the medical community for a more simple and rapid approach for processing and analyzing low volume sputum samples In this SBIR project we will address this unmet need by developing and commercializing acoustofluidic i e the fusion of acoustics and microfluidics technologies for point of care automated sputum processing and analysis In Phase I Ascent has successfully demonstrated the utility and feasibility of the proposed devices by meeting or exceeding the acceptable values of each of the five key parameters identified in the Measures of Success In Phase II our commercialization activities will improve performance of the disposable acoustofluidic chips develop self contained beta testing ready prototypes and validate their performance with a pilot clinical feasibility study The proposed system will have the following features ability to perform accurate sputum analysis over a much wider sample size range volume L than the conventional approaches volume L automation and low turnaround time biohazard containment and low cost point of care devices With these features we expect that once demonstrated the proposed acoustofluidic platform will not only be an excellent replacement for existing sputum processing analysis tools but will also fulfill many unmet needs for applications where the amount of sputum induced from asthmatic patients is not enough to run the standard tests and or the expertise and equipment to perform this analysis are not available such as most practice locations outside of large hospitals Project Narrative The proposed project is to develop tools that can perform automated accurate sputum processing and analysis using low volume samples Advances achieved in the proposed project will be critical in the development of personalized treatments for asthma


Grant
Agency: National Science Foundation | Branch: | Program: STTR | Phase: Phase II | Award Amount: 750.00K | Year: 2015

The broader/commercial impact of the Small Business Technology Transfer (STTR) Phase II project will be a cell sorter, a new research tool for life science research, animal reproduction, and cell-based therapy. In the past decade, cell sorters have become vital in many fields, such as molecular and cellular biology, immunology, plant biology, animal reproduction, and medical diagnostics and therapeutics. Despite their significant impact, current cell sorters have the following drawbacks: high equipment and maintenance costs, significant bio-safety concerns, and reduced cell viability and function. These drawbacks reduce the effectiveness of cell sorters in many important research studies and clinical applications. Enabled by this innovation, researchers will be able to better understand the causes of diseases, identify new therapies, and test new drugs and vaccines. It also has the potential to improve dairy production efficiency, and aid medical doctors in making better decisions about diagnosis and treatment. In Phase II, the goal is to improve performance of the instrument, and validate the performance with end users. This STTR Phase II project will demonstrate the feasibility of a microfluidic-based, bio-compatible, bio-safe, fluorescence-activated cell sorter. Cell sorters are powerful, high-throughput, single-cell characterization and purification tools that are vital for labs in fields such as molecular biology, pathology, plant biology, stem cell biology, and medical diagnostics. The technology is based on acoustofluidic (i.e., the fusion of acoustics and microfluidics) cell sorting chips that preserve the integrity and functionality of sorted cells. Current cell sorting systems reduce cell viability, integrity, and cell function due to high shear stress, high impact force, and high driving voltage, which reduces their effectiveness as a research tool, and in clinical applications. Unlike current cell sorters that use electrostatic force to sort cells, which require 12,000 V of driving voltage, the proposed technology uses acoustic tweezers to sort cells, and requires only 10 V, which significantly reduces cell damage. Compared with existing cell sorters, the proposed microfluidic cell sorter will have the following advantages: 1) high bio-compatibility; 2) high bio-safety; and 3) lower costs and lower maintenance. In addition, the cell sorter will be more accessible to researchers and address existing unmet needs in the market (e.g., sorting fragile or sensitive cells while preserving high viability and function). This will accelerate research findings and improve diagnostics and therapeutics.


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 270.00K | Year: 2014

This Small Business Technology Transfer (STTR) Phase I project will demonstrate the feasibility of microfluidic-based, bio-compatible, bio-safe, fluorescence-activated cell sorters. Cell sorters are powerful, high-throughput, single-cell characterization and purification tools that are vital for labs in fields such as molecular biology, pathology, plant biology, stem cell biology, and medical diagnostics. Despite their significant impact, current commercial cell sorters have a variety of drawbacks. High instrument costs (average cost: ~$500,000), high maintenance (maintenance cost: ~$30,000 per year; highly trained personnel needed), significant biosafety concerns, and reduction of cell viability and functionality make conventional cell sorters less effective in many applications and inhibit their widespread use. To address limitations of existing cell sorters, an innovative approach is proposed that features two key technologies: 1) a microfluidic drifting based cell-focusing technique; and 2) a cell-deflection technique using chirped interdigitated transducers (IDTs). The proposed microfluidic cell sorter eliminates the generation of hazardous aerosols and preserves high cell viability and functions.

The broader impact/commercial potential of this project, if successful, will be the development of the most bio-compatible and bio-safe cell sorters for researchers and scientists. According to a 2011 BCC research report, the instrument market for flow cytometers and cell sorters accounted for $1.4 billion in 2010 and is expected to grow at a CAGR of 9.8% from 2010 to 2015 ($2.2 billion). The served available market (SAM) is estimated to be ~$200 million. Compared with the existing cell sorters, the proposed microfluidic cell sorter will have the following advantages: 1) high bio-compatibility; 2) high bio-safety; and 3) low costs and low maintenance. In addition, the cell sorter will be more accessible to researchers and address existing unmet needs in the market (e.g., sorting fragile or sensitive cells while preserving high viability and functions). It will accelerate research findings and improve diagnostics and therapeutics. It will also create more job opportunities as the company grows.


Grant
Agency: National Science Foundation | Branch: | Program: STTR | Phase: Phase I | Award Amount: 225.00K | Year: 2014

This Small Business Technology Transfer (STTR) Phase I project will demonstrate the feasibility of microfluidic-based, bio-compatible, bio-safe, fluorescence-activated cell sorters. Cell sorters are powerful, high-throughput, single-cell characterization and purification tools that are vital for labs in fields such as molecular biology, pathology, plant biology, stem cell biology, and medical diagnostics. Despite their significant impact, current commercial cell sorters have a variety of drawbacks. High instrument costs (average cost: ~$500,000), high maintenance (maintenance cost: ~$30,000 per year; highly trained personnel needed), significant biosafety concerns, and reduction of cell viability and functionality make conventional cell sorters less effective in many applications and inhibit their widespread use. To address limitations of existing cell sorters, an innovative approach is proposed that features two key technologies: 1) a "microfluidic drifting" based cell-focusing technique; and 2) a cell-deflection technique using chirped interdigitated transducers (IDTs). The proposed microfluidic cell sorter eliminates the generation of hazardous aerosols and preserves high cell viability and functions. The broader impact/commercial potential of this project, if successful, will be the development of the most bio-compatible and bio-safe cell sorters for researchers and scientists. According to a 2011 BCC research report, the instrument market for flow cytometers and cell sorters accounted for $1.4 billion in 2010 and is expected to grow at a CAGR of 9.8% from 2010 to 2015 ($2.2 billion). The served available market (SAM) is estimated to be ~$200 million. Compared with the existing cell sorters, the proposed microfluidic cell sorter will have the following advantages: 1) high bio-compatibility; 2) high bio-safety; and 3) low costs and low maintenance. In addition, the cell sorter will be more accessible to researchers and address existing unmet needs in the market (e.g., sorting fragile or sensitive cells while preserving high viability and functions). It will accelerate research findings and improve diagnostics and therapeutics. It will also create more job opportunities as the company grows.

Loading Ascent Bio-Nano Technologies, Inc. collaborators
Loading Ascent Bio-Nano Technologies, Inc. collaborators